Paul Studenic, ACR 2022: The 2022 revision of the ACR/EULAR remission criteria for rheumatoid arthritis
ACR and EULAR endorsed provisional criteria, both Boolean and index-based, to define remission in rheumatoid arthritis (RA) over 10 years ago, in 2022 a revision of the remission criteria has been made. touchIMMUNOLOGY were delighted to speak with Dr. Paul Studenic (Medical University of Vienna, Vienna, Austria) to discuss the limitations of the Boolean and index-based criteria previously used and the revisions made in 2022.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract ‘2022 Revision of the ACR/EULAR Remission Criteria for Rheumatoid Arthritis.‘ (Abstract number: 1414) was presented at the ACR Convergence, November 10–14, 2022.
Questions
- What were the limitations of the Boolean and index-based criteria used by the ACR and EULAR to define remission in RA? (0:16)
- What are the revisions of the Boolean remission criteria? (2:41)
Disclosures: Paul Studenic has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ACR Convergence 2022.
